DreamCIS

DreamCIS EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DreamCIS (223250.KQ) as of Oct 29, 2026 is 5.24 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 6.25 B KRW — a change of -16.21% (lower).

EBITDA

5.24 BKRW

YoY

-16.21%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DreamCIS is 2025 5.24 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DreamCIS was 2024 6.25 B KRW. It decreases by -16.21% lower compared to the previous year.

The DreamCIS EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
3.64 B KRW
Jan 1, 2019
4.50 B KRW
Jan 1, 2020
5.00 B KRW
Jan 1, 2021
3.82 B KRW
Jan 1, 2022
6.65 B KRW
Jan 1, 2023
2.72 B KRW
Jan 1, 2024
6.25 B KRW
Jan 1, 2025
5.24 B KRW
The DreamCIS EBITDA history
YEAREBITDAYoY
5.24 BKRW-16.21%
6.25 BKRW+129.52%
2.72 BKRW-59.08%
6.65 BKRW+74.03%
3.82 BKRW-23.57%
5.00 BKRW+11.26%
4.50 BKRW+23.53%
3.64 BKRW-467.08%
-991.64 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

DreamCIS Stock analysis

What does DreamCIS do? DreamCIS Inc. is a company based in Seoul, South Korea, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 22, 2020, with its stock listed under the ticker 223250.KQ and ISIN KR7223250002. DreamCIS Inc. provides clinical online information and consultation services, focusing on regulatory post-marketing surveillance (rPMS), clinical trials, and non-interventional studies (NIS). The company serves both domestic and international markets, offering its services to clients seeking support in clinical research and regulatory compliance. Its headquarters are located in Seoul, South Korea. The company's website is http://www.dreamcis.com/, which serves as a primary source for further information about its services and operations. DreamCIS Inc. does not provide detailed information about its founding year, specific leadership, or financial figures beyond its IPO date, and no acquisitions or additional product names are mentioned in the provided data. The company's services are primarily aimed at facilitating clinical research and ensuring adherence to regulatory standards in the life sciences sector. DreamCIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DreamCIS stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DreamCIS is 5.24 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DreamCIS changed from 6.25 B KRW to 5.24 B KRW, representing a -16.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) DreamCIS since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s DreamCIS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — DreamCIS

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — DreamCIS